WELCOME TO The PHARMACEUTICAL REPORT
Siegfried Holding AG
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Prnewswire | August 18, 2020
Kimera® Labs Inc, a privately held clinical stage biotechnology company, announces the filing of an extended FDA Investigational New Drug (IND) application to study the treatment of COVID-19 related inflammatory disease using Kimera's first-in-class XoGlo® isolated placental mesenchymal stem cell-based exosomes. Founded in 2012, Kimera® generated the first publicly available isolated exosome product and has treated over 35,000 thousand patients for a variety of investigatio...
Prnewswire | May 27, 2020
Rx Savings Solutions announced today its entrance into the mid-market segment with the expansion of their personalized prescription drug transparency program to midsize organizations. With this comprehensive solution driven by more than 29,000 clinical recommendations, more benefit leaders of all sizes can provide a valuable resource for members to engage with personalized savings options. As pharmacy continues to be the most predictable and repeated spend in healthcare, Rx Savings Solutions aim...
Cancer Prevention Pharmaceuticals, CPP-1X/sul | June 29, 2020
Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for CPP-1X/sul for treatment of adults with familial adenomatous polyposis (FAP).
FAP is a rare genetic disease that if left untreated progresses to colorectal cancer in nearly 100% of patients. The clinical...
STAT | January 28, 2020
Money talks in Washington, D.C., and no sector of the economy speaks more loudly than the pharmaceutical and biotech industry. Its flow of cash has fostered an epidemic of medication overload. Over the past five years, pharma has spent about $1.2 billion lobbying federal lawmakers, far more than any other industry. The industry has massive influence over public policy, much of it devoted in recent months to hindering legislative efforts to lower drug prices. In addition to keeping prices high, t...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE